A61K 31/7064 (20130101)
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
Cheng, Jing Q., "Effective treatment of esophageal adenocarcinoma using triciribine and related compounds" (2016). USF Patents. 892.
University of South Florida